Ethical concerns with online direct-to-consumer pharmaceutical companies
Ethical concerns with online direct-to-consumer pharmaceutical companies
复制标题
DOI：
10.1136/medethics-2019-105776
复制
发表时间：
2020-03-01
影响因子：
4.1
通讯作者：
Milner, Joseph
中科院分区：
文献类型：
--
作者：
Curtis, Henry;Milner, Joseph
近年来，在线直接面向消费者的制药公司已经成为个人获得处方药的替代方法。虽然这些公司有崇高的目标，以提供更容易，更具有成本效益的药物，但这些公司都发出处方（通过完全在线的医疗评论，医生和患者之间没有直接接触）以及分发和运输药物的事实产生了多种伦理问题。本文主要探讨两个方面。首先，这种模式造成了这些公司雇佣的医生开处方的利益冲突。其次，缺乏医生的直接接触可能对潜在患者有害。在分析这些问题后，本文认为，应该进一步考虑对这些公司的监管和监督。
In recent years, online direct-to-consumer pharmaceutical companies have been created as an alternative method for individuals to get prescription medications. While these companies have noble aims to provide easier, more cost-effective access to medication, the fact that these companies both issue prescriptions (via entirely online medical reviews that can have no direct contact between physician and patient) as well as distribute and ship medications creates multiple ethical concerns. This paper aims to explore two in particular. First, this model creates conflicts of interest for the physicians hired by these companies to write prescriptions. Second, the lack of direct contact from physicians may be harmful to prospective patients. After analysing these issues, this paper argues that there ought to be further consideration for regulation and oversight for these companies.